Document is current
Any future updates will be listed below
-
Authors
Codeluppi, S. A.
Xu, M.
Bansal, Y.
Lepack, A. E.
Duric, V.
Chow, M.
Muir, J.
Bagot, R. C.
Licznerski, P.
Wilber, S. L.
Sanacora, G. https://orcid.org/0000-0003-3722-8829
Sibille, E. https://orcid.org/0000-0001-5832-6570
Duman, R. S. https://orcid.org/0000-0001-8690-8439
Pittenger, C. https://orcid.org/0000-0003-2117-9321
Banasr, M. https://orcid.org/0000-0002-9347-7523
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (202110MFE-472592-FPP-CEAH-93191, 201810GSD-4221 05-DRA-CFAA-297096, PGT165852)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIH-NIMH R01 MH081211)
Brain and Behavior Research Foundation
Centre de Toxicomanie et de Santé Mentale | Campbell Family Mental Health Research Institute
- License Information
-
More Information
Article History
Received: 21 June 2023
Revised: 17 August 2023
Accepted: 29 August 2023
First Online: 11 September 2023
Competing interests
: In the past 3 years GS has served as consultant to Ancora, Aptinyx, Atai, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio, Cowen, Denovo Biopharma, ECR1, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, Gilgamesh, Intra-Cellular Therapies, Janssen, KOA Health, Levo therapeutics, Lundbeck, Merck, MiCure, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Relmada Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Valeant, Vistagen Therapeutics, and XW Labs; and received research contracts from Johnson & Johnson/Janssen, Merck, and the Usona Institute over the past 36 months. GS holds equity in Biohaven Pharmaceuticals, Freedom Biosciences, Gilead, Relmada, and Tetricus. GS is a co-inventor on a US patent (#8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018, by Yale University Office of Cooperative Research. Conflict of Interest office. CP consults for Biohaven Pharmaceuticals, Transcend Therapeutics, Ceruvia Lifesciences, Freedom Biosciences, Nobilis Therapeutics, and F-Prime Ventures, and has received research from Biohaven, Transcend, and Freedom; these relationships are not related to the work described here. AL is employed by Bluerock Pharmaceuticals. Yale University has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship. The University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s. SC, YB, MC, PL, VD, RD, JM, RB, ES, and MB have no conflict of interest to disclose.
